This webpage contains a listing of the permanent changes made to the online text of CDC Health Information for International Travel 2010 since its May 2009 hardcopy release.

Changes are also indicated within the online sections.

Remember to also check for current recommendations related to outbreaks or emerging situations in Travel Notices that may differ temporarily from recommendations in the Yellow Book.

 

Content Changes

Oral rehydration salts (ORS) solution composition (Table 2-25), in Chapter 2

October 16, 2009

The previously listed amounts of ORS ingredients had not been updated to current World Health Organization and UNICEF recommended amounts. These amounts have been updated.

Revised Recommendations for Meningococcal Vaccine

October 15, 2009

The Advisory Committee on Immunization Practices (ACIP) has revised its recommendations for booster doses of meningococcal conjugated vaccine (MCV4, Menactra, sanofi pasteur) for persons ages 2 through 55 years who remain at increased risk for meningococcal disease. For people previously vaccinated with MCV4 or MPVS4 who remain at an increased risk for meningococcal disease (see Meningococcal Disease section for who is considered to be at increased risk for meningococcal disease), ACIP recommends the following:

• Children previously vaccinated at ages 2 through 6 years should receive an additional dose of MCV4 three years after their previous meningococcal vaccine and every five years thereafter, if at continued risk.
• Persons previously vaccinated at ages 7 through 55 years should receive an additional dose of MCV4 five years after their previous dose and every five years thereafter, if at continued risk.

This information has been updated in the following sections:

• Table 2.01: Revaccination (booster) schedules in General Recommendations for Vaccination and Immunoprophylaxis, Chapter 2
• Preventive Measures for Travelers section of Meningococcal Disease, Chapter 2
• Meningococcal Vaccine section of Vaccine Recommendations for Infants and Children, Chapter 7
• Table C.01: Travel vaccine summary in the Appendices

Reference: CDC. Updated Recommendation from the Advisory Committee on Immunization Practices (ACIP) for revaccination of persons at prolonged increased risk for meningococcal disease. MMWR 2009;58:1042–3.

Hepatitis B, in Chapter 4

October 6, 2009

An error has been corrected in the Special Situations section of the Hepatitis B vaccine information. Although not approved by FDA, the correct accelerated schedule for monovalent hepatitis B vaccines, sometimes used for those at higher risk for hepatitis B who are traveling to endemic areas at short notice, is 0, 7, and 21–28 days.

Dengue Fever (DF) and Dengue Hemorrhagic Fever (DHF), in Chapter 5

August 24, 2009

Because dengue fever is now a nationally notifiable disease, information in the Clinical Presentation section of "Dengue Fever (DF) and Dengue Hemorrhagic Fever (DHF)" has been updated to mirror the official case definitions of dengue fever, dengue hemorrhagic fever, and dengue shock syndrome.

Vivotif Vaccine Information: Typhoid and Paratyphoid Fever and Drug–Vaccine and Drug–Drug Interactions, both in Chapter 2

July 27, 2009

An error in the Vivotif vaccine manufacturer’s information has been corrected in the text of the Typhoid and Paratyphoid Fever section. Vivotif vaccine is manufactured by Crucell/Berna.

An error was made in the hardcopy text describing the recommended time between completion of the vaccine series and travel. The oral typhoid vaccine (Vivotif) should be completed 7 days prior to traveling, not 14 days. This information has been corrected in the Drug–Drug and Drug–Vaccine Interactions section.